NZ335003A - Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1) - Google Patents

Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)

Info

Publication number
NZ335003A
NZ335003A NZ335003A NZ33500397A NZ335003A NZ 335003 A NZ335003 A NZ 335003A NZ 335003 A NZ335003 A NZ 335003A NZ 33500397 A NZ33500397 A NZ 33500397A NZ 335003 A NZ335003 A NZ 335003A
Authority
NZ
New Zealand
Prior art keywords
mpif
inhibitory factor
myeloid progenitor
methods
disease states
Prior art date
Application number
NZ335003A
Other languages
English (en)
Inventor
Reiner L Gentz
Vikram Patel
Brent L Kreider
Jun Zhang
Michael Antonaccio
Donna Mendrick
Pablo Jimenez
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of NZ335003A publication Critical patent/NZ335003A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ335003A 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1) NZ335003A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2730096P 1996-09-30 1996-09-30
US2729996P 1996-09-30 1996-09-30
PCT/US1997/017505 WO1998014582A1 (fr) 1996-09-30 1997-09-30 Compositions therapeutiques et procedes de traitement de maladies utilisant le facteur-1 inhibiteur des precurseurs myeloides (mpif-1), le facteur inhibiteur des colonies de monocytes (m-cif) et le facteur-4 inhibiteur de la migration des macrophages (mip-4)

Publications (1)

Publication Number Publication Date
NZ335003A true NZ335003A (en) 2000-11-24

Family

ID=26702293

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ335003A NZ335003A (en) 1996-09-30 1997-09-30 Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)
NZ506135A NZ506135A (en) 1996-09-30 1997-09-30 Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ506135A NZ506135A (en) 1996-09-30 1997-09-30 Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis

Country Status (8)

Country Link
EP (1) EP0941330A1 (fr)
JP (1) JP2001500382A (fr)
KR (1) KR20030097607A (fr)
CN (1) CN1239510A (fr)
AU (1) AU4657697A (fr)
CA (1) CA2267193A1 (fr)
NZ (2) NZ335003A (fr)
WO (1) WO1998014582A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6488925B2 (en) 1993-12-22 2002-12-03 Human Genome Sciences, Inc. Macrophage inflammatory protein-4 (MIP-4) polypeptides
US6811773B1 (en) 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6001606A (en) * 1994-03-08 1999-12-14 Human Genome Sciences, Inc. Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby
US6451562B1 (en) 1993-12-22 2002-09-17 Human Genome Sciences, Inc. Polypeptides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) polynucleotides
US6495129B1 (en) 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
AU777297B2 (en) * 1996-09-30 2004-10-07 Human Genome Sciences, Inc. Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1), monocyte colony inhibitory factor (M-CIF), and macrophage inhibitory factor-4 (MIP-4)
US6632425B1 (en) 1997-03-20 2003-10-14 Human Genome Sciences, Inc. Chemokine compositions
WO2000028035A1 (fr) 1998-11-10 2000-05-18 Human Genome Sciences Inc. CHEMOKINE β-7
EP1142908A4 (fr) * 1999-01-07 2002-05-22 Takeda Chemical Industries Ltd Procede de production de proteines activees
AU1083401A (en) * 1999-10-14 2001-04-23 Human Genome Sciences, Inc. Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1)
EP1176200A3 (fr) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Utilisation des polypeptides ou leurs acides nucléiques pour le diagnose ou traitement des maladies de la peau ou de la cicatrisation de blessures et leurs utilisations pour l'identification des substances pharmacologiquement actives
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
KR100867257B1 (ko) * 2001-10-09 2008-11-11 케모센트릭스, 인크. 포밀 펩티드 수용체 유사 1 수용체에 대한 리간드로유용한 조성물 및 이의 사용 방법
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
US20070244037A1 (en) * 2003-10-24 2007-10-18 Tap Pharmaceutical Products Inc Human Chemokine HCC-1 Polypeptides To Improve Stem Cell Transplantation
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
EP1738175A2 (fr) * 2004-03-22 2007-01-03 Novartis AG Le chemokine ccl18 en tant que biomarqueur biologique
US8221995B2 (en) 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
WO2009052557A1 (fr) * 2007-10-22 2009-04-30 St Vincent's Hospital Sydney Limited Procédés de pronostic
CN113215085B (zh) * 2021-05-07 2024-05-10 澳门大学 一种脂类物质添加剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2214484T3 (es) * 1993-12-22 2004-09-16 Human Genome Sciences, Inc. Proteinas inflamatorias de macrofagos mip-3, mip-4 y mip-1 gamma.
ATE218616T1 (de) * 1993-12-24 2002-06-15 Forssmann Wolf Georg Humanes zirkulierendes cytokin cc-1
US5602008A (en) * 1994-11-29 1997-02-11 Incyte Pharmaceuticals, Inc. DNA encoding a liver expressed chemokine
EP0871672A4 (fr) * 1995-05-05 1999-05-12 Human Genome Sciences Inc Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine
AU711573B2 (en) * 1995-09-29 1999-10-14 Smithkline Beecham Corporation Short forms of chemokine beta-8
JP2001519757A (ja) * 1995-10-24 2001-10-23 スミスクライン・ビーチャム・コーポレイション 幹細胞動員のための新規ケモカイン

Also Published As

Publication number Publication date
NZ506135A (en) 2002-11-26
CA2267193A1 (fr) 1998-04-09
AU4657697A (en) 1998-04-24
KR20030097607A (ko) 2003-12-31
WO1998014582A1 (fr) 1998-04-09
CN1239510A (zh) 1999-12-22
EP0941330A1 (fr) 1999-09-15
JP2001500382A (ja) 2001-01-16

Similar Documents

Publication Publication Date Title
NZ335003A (en) Therapeutic compositions and methods for treating disease states with myeloid progenitor inhibitory factor-1 (MPIF-1)
EP0735893A4 (fr) Alteration de la reponse immunitaire a l'aide de peptides se liant a des alleles pan dr
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
HK184896A (en) Pharmaceutical composition comprising loratadine ibuprofen and pseudoephedrine
ZA946142B (en) Therapeutic heterocycles
HUS1400034I1 (hu) Dialkil-fumarátok alkalmazása autoimmun betegségek kezelésére szolgáló gyógyászati készítmények elõállítására
GB9806632D0 (en) Peptide factor
ES2091906T3 (es) Composiciones que comprenden derivados de un peptido de omega-conotoxina y su uso en el tratamiento del daño neuronal relacionado con la isquemia.
MY106272A (en) Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants.
DE69912434D1 (de) Pharmazeutische zusammensetzung zur behandlung einer funktionalen dyspepsie und/oder des reizdarmsyndroms und die verwendung neuer substanzen in dieser zusammensetzung
HK1123741A1 (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders (dextromethorphan)(quinidine)
HK1019856A1 (en) Therapeutic uses of bpi protein products for human meningococcemia
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
JPH06329549A (ja) インターロイキン１２のｐ４０サブユニットを含んでなる医薬
CA2068871A1 (fr) Fgf-4 non glycosyle et compositions a base de ce produit
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
CA2123315A1 (fr) Agents therapeutiques qui sont des antagonistes ou agonistes partiels de l'interleukine 4
DE69911401D1 (en) Immunoregulator
GR3034743T3 (en) Growth hormone antagonists.
CA2094275A1 (fr) Methodes et compositions pour le traitement de maladies cytoproliferatives
HU9202075D0 (en) Bcrf1 proteins of gamma-interferon inhibiting effect
NO983238L (no) Exodus kjemokin materialer og fremgangsmÕter
WO1996020950A3 (fr) Compositions et therapies pour le traitement de la polyarthrite rhumatoide
AU4762893A (en) Hla-dr3 blocking peptides and their use in the treatment of hla-dr3 associated autoimmune diseases.
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)